Abrams Shareholder of: Novartis, Employee of: Novartis, K. Childhood Health Assessment Questionnaire [CHAQ]), pain (measured on a visual analog scale [VAS] of 0-100 mm as part of the CHAQ), and physical (phs) and psychosocial (pss) health status in 5-18 year old pts., according to the Child Health Questionnaire-Parent Form (CHQ-PF50). == Results == In Trial 1, CAN treatment was associated with a significant improvement in CHAQ disability score (estimated difference [ED] of -0.69 over time vs PBO 6-Benzylaminopurine in the least square mean [LSM] change from baseline [BL] [p = 0.0002]), which was ~3.6 the minimal clinically important difference of -0.19. The LSM in overall pain intensity were significantly lower (both p < 0.0001) in the CAN group vs PBO both at Day 15 (ED, -46.42) and Day 29 (ED, -41.86). CHQ-PF50 phs and pss scores also showed significant improvements over time (ED CAN vs PBO in LSM change from BL, 12.07 and 7.28; p < 0.005 for both). Improvements in CHAQ disability, CHQ-PF50 phs and pss, and VAS pain scores were also observed in Trial 2 (Table1). == Table 1. == Patient- or Parent-reported functional ability and hrqol parameters in Trial 2 Results are based on patients with both baseline and post-baseline values. N18 years old. == Conclusion == Treatment with CAN demonstrated rapid, marked and continued improvement in patient-reported functional ability and hrqol of SJIA patients. == Disclosure of interest == P. Quartier Grant/Research Support from: Abbvie, Chugai-Roche, Novartis, Pfizer, Consultant for: Abbvie, BMS, Chugai-Roche, Novartis, Pfizer, Servier, Sweedish Orphan Biovitrum, Speakers Bureau: Chugai-Roche, Novartis, Pfizer, N. Ruperto Grant/Research Support from: To Gaslini Hospital: Abbott, Astrazeneca, BMS, Centocor Research & Development, Eli Lilly and Company, "Francesco Angelini", Glaxo Smith & Kline, Italfarmaco, Novartis, Pfizer 6-Benzylaminopurine Inc., Roche, Sanofi Aventis, Schwarz Biosciences gmbh, Xoma, Wyeth Pharmaceuticals Inc., Speakers Bureau: Astrazeneca, Bristol Myers and Squibb, Janssen Biologics B.V., Roche, Wyeth/Pfizer, N. Wulffraat Consultant for: Novartis, Pfizer, Roche, H. Brunner Consultant for: Novartis, Genentech, Medimmune, EMD Serono, AMS, Pfizer, UCB, Jannsen, Speakers Bureau: Genentech, R. Brik Grant/Research Support from: Novartis, Consultant for: Novartis, L. Mccann: None declared., H. Foster Grant/Research Support from: Pfizer, biomarin, Speakers Bureau: Pfizer, M. Frosch: None declared., V. Gerloni: None declared., L. Harel: None declared., C. Len: None declared., K. Houghton: None declared., R. Joos: None declared., K. Abrams Shareholder of: Novartis, Employee of: Novartis, K. Lheritier Shareholder of: Novartis, Employee of: Novartis, S. Kessabi Employee 6-Benzylaminopurine of: Novartis, A. Martini Grant/Research Support from: Abbott, Astrazeneca, Bristol Myers and Squibb, Janssen Biologics B.V., Ely Lilly and Company, “Francesco Angelini”, Glaxo Smith & Kline, Italfarmaco, Novartis, Pfizer ARHGEF2 Inc., Roche, Sanofi Aventis, Schwarz Bisciences, gmbh, Xoma, Wyeth Pharmaceuticals Inc.(Consulting fee). The GASLINI hospital which is a public hospital where I work as full time employee has received contributions to support the research activities of the network of PRINTO (http://www.printo.it), Consultant for: Abbott, Astrazeneca, Bristol Myers and Squibb, Janssen Biologics B.V., Ely Lilly and Company, Francesco A, Glaxo Smith & Klime, Italfarmaco, Novartis, Pfizer Inc., Roche, Sanofi Aventis, Schwarz Biosciences gmbh, Xoma, Wyeth Pharmaceuticals, Speakers Bureau: Astellas, Astrazeneca, Bristol Myers and Squibb, Glaxo Smith & Kline, Italfarmaco, medimmune, Novartis, D. Lovell Grant/Research Support from: NIH, Consultant for: Astra-Zeneca, Centocor, Jannsen, Wyeth, Amgen, Bristol-Meyers Squibb, Abbott, Pfizer, Regeneron, Hoffman La-Roche, Novartis, Genentech, Speakers Bureau: Genentech, Roche..